Breaking News Instant updates and real-time market news.

CELG

Celgene

$95.53

0.04 (0.04%)

07:42
05/13/19
05/13
07:42
05/13/19
07:42

Celgene's POMALYST granted breakthrough therapy designation from FDA

Celgene Corporation announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to POMALYST for the treatment of patients with human immunodeficiency virus-positive Kaposi sarcoma who have previously received systemic chemotherapy, as well as patients with HIV-negative Kaposi's sarcoma. Kaposi sarcoma is a multicentric tumor caused by Kaposi sarcoma-associated herpesvirus, also called human herpesvirus-8. Patients suffer multiple lesions on the skin and oral mucosa, and at times other organs such as the lungs or gastrointestinal mucosa. Kaposi sarcoma most commonly arises in persons infected with HIV. The Breakthrough Therapy designation was granted by the FDA on the basis of the results of a clinical study performed under a Cooperative Research and Development Agreement by a team led by Dr. Robert Yarchoan, of the HIV and AIDS Malignancy Branch within the Center for Cancer Research of the National Cancer Institutes. The results of that study, published in the Journal of Clinical Oncology evaluated POMALYST in patients with Kaposi sarcoma, with or without HIV infection, many of whom had received prior cytotoxic chemotherapy. Celgene plans to submit a supplemental New Drug Application for POMALYST in this disease area by the end of 2019. Celgene also has two additional studies planned in this disease. In partnership with the AIDS Malignancy Consortium, a U.S. multicenter study will be performed to confirm and extend the results of the NCI study. The AMC is also sponsoring a second study in sub-Saharan Africa, where Kaposi sarcoma continues to be a serious problem. This program is a part of the Celgene Global Health effort to discover and develop new drugs for diseases that affect patients in the lower- and middle-income countries where health systems and medical resources are less advanced.

  • 14

    May

  • 18

    May

  • 31

    May

  • 27

    Jun

  • 03

    Sep

CELG Celgene
$95.53

0.04 (0.04%)

05/03/19
LEHM
05/03/19
UPGRADE
Target $55
LEHM
Overweight
Bristol-Myers upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Geoffrey Meacham upgraded Bristol-Myers Squibb (BMY) to Overweight from Equal Weight and raised his price target for the shares to $55 from $53. The analyst says increased confidence in the Celgene (CELG) acquisition successfully closing makes him more bullish on Bristol-Myers shares. Increased optionality from the Celgene pipeline along with a "differentiated" growth profile and earnings power over the next few years make the combined company attractive at current share levels, Meacham tells investors in a research note.
05/03/19
LEHM
05/03/19
DOWNGRADE
Target $102
LEHM
Equal Weight
Celgene downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoffrey Meacham downgraded Celgene (CELG) to Equal Weight from Overweight to reflect his increased confidence that the takeover by Bristol-Myers (BMY) will close. The analyst, who upgraded Bristol-Myers this morning to Overweight, says his thesis on Celgene has played out. He keeps a $102 price target for the shares.
05/03/19
JPMS
05/03/19
INITIATION
Target $62
JPMS
Overweight
Bristol-Myers reinstated with an Overweight at JPMorgan
Following a period of restriction, JPMorgan analyst Chris Schott reinstated coverage of Bristol-Myers Squibb (BMY) with an Overweight rating and $62 price target. The analyst had an Overweight rating on the shares and price target of $70 prior to restriction. While the company's proposed acquisition of Celgene (CELG) has been controversial, the shares are "too inexpensive to ignore," Schott tells investors in a research note. He sees the combined company generating 2020 earnings of $6.50 per share and 3% sales/6% earnings growth off of this base through 2025.
05/07/19
PIPR
05/07/19
NO CHANGE
Target $23
PIPR
Overweight
Sutro regaining U.S. rights from Celgene a 'clear positive,' says Piper Jaffray
The FDA has cleared the investigational new drug application for Sutro Biopharma's Celgene-partnered BCMA ADC, which is on track to enter the clinic in 2019, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. In addition, Celgene not exercise an option on a second program, meaning Sutro has regained U.S. rights, adds the analyst. He views this as a "clear positive" for Sutro, saying the company has regained the U.S. rights to "another exciting preclinical program." Importantly, there is no impact on Sutro's wholly-owned clinical programs, Tenthoff adds. He reiterates an Overweight rating on Sutro Biopharma with a $23 price target.

TODAY'S FREE FLY STORIES

AAPL

Apple

$202.73

-9.82 (-4.62%)

, AMZN

Amazon.com

$1,752.00

-52 (-2.88%)

09:03
08/24/19
08/24
09:03
08/24/19
09:03
Periodicals
Costco the most 'woke' company out there, Barron's says »

Earlier this week, the…

AAPL

Apple

$202.73

-9.82 (-4.62%)

AMZN

Amazon.com

$1,752.00

-52 (-2.88%)

BLK

BlackRock

$407.29

-11.55 (-2.76%)

WMT

Walmart

$110.83

-1.07 (-0.96%)

COST

Costco

$274.16

-5.7 (-2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 25

    Sep

  • 03

    Oct

  • 27

    Oct

  • 13

    Nov

  • 14

    Nov

MMM

3M

$155.84

-5.04 (-3.13%)

08:58
08/24/19
08/24
08:58
08/24/19
08:58
Periodicals
3M stock still not looking like a bargain, Barron's says »

3M shares are down by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

ULTA

Ulta Beauty

$322.34

-12.5 (-3.73%)

08:56
08/24/19
08/24
08:56
08/24/19
08:56
Periodicals
Ulta Beauty bucking downbeat retail trends, Barron's says »

Ulta Beauty has been one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 25

    Sep

CMCSK

Comcast

$0.00

(0.00%)

, CMCSA

Comcast

$42.47

-1.29 (-2.95%)

08:49
08/24/19
08/24
08:49
08/24/19
08:49
Periodicals
Roku working for investors, Barron's says »

The streaming war…

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$42.47

-1.29 (-2.95%)

DIS

Disney

$131.70

-4.37 (-3.21%)

NFLX

Netflix

$291.40

-5.47 (-1.84%)

AAPL

Apple

$202.73

-9.82 (-4.62%)

ROKU

Roku

$137.77

-1.35 (-0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 05

    Sep

  • 23

    Sep

  • 27

    Oct

NSRGY

Nestle

$0.00

(0.00%)

08:44
08/24/19
08/24
08:44
08/24/19
08:44
Periodicals
Nestle stock looking appetizing after big gain, Barron's says »

Nestle is having a great…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$291.40

-5.47 (-1.84%)

, DIS

Disney

$131.70

-4.37 (-3.21%)

08:39
08/24/19
08/24
08:39
08/24/19
08:39
Periodicals
Football season is back, key moment for TV future, Barron's says »

On Sept. 5, when the…

NFLX

Netflix

$291.40

-5.47 (-1.84%)

DIS

Disney

$131.70

-4.37 (-3.21%)

FOXA

Fox Corp.

$31.76

-1.29 (-3.90%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$42.47

-1.29 (-2.95%)

CBS

CBS

$41.39

-2.06 (-4.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 23

    Sep

  • 27

    Oct

AMZN

Amazon.com

$1,752.00

-52 (-2.88%)

, FDX

FedEx

$151.94

-6.17 (-3.90%)

08:05
08/24/19
08/24
08:05
08/24/19
08:05
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,752.00

-52 (-2.88%)

FDX

FedEx

$151.94

-6.17 (-3.90%)

UPS

UPS

$111.29

-3.91 (-3.39%)

F

Ford

$8.76

-0.27 (-2.99%)

GM

General Motors

$36.06

-1.19 (-3.19%)

DDAIF

Daimler AG

$0.00

(0.00%)

HMC

Honda

$22.90

-0.32 (-1.38%)

TM

Toyota

$127.94

-1.69 (-1.30%)

VWAGY

Volkswagen

$0.00

(0.00%)

AAPL

Apple

$202.73

-9.82 (-4.62%)

FB

Facebook

$177.69

-4.39 (-2.41%)

TWTR

Twitter

$41.01

-1.16 (-2.75%)

GOOGL

Alphabet Class A

$1,154.66

-35.75 (-3.00%)

GOOG

Alphabet

$1,151.72

-36.81 (-3.10%)

ADM

Archer Daniels

$37.44

-0.48 (-1.27%)

REGI

Renewable Energy

$11.65

0.61 (5.53%)

GPRE

Green Plains

$7.34

-0.68 (-8.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 15

    Sep

  • 17

    Sep

  • 17

    Sep

  • 18

    Sep

  • 19

    Sep

  • 23

    Sep

  • 24

    Sep

  • 23

    Oct

  • 23

    Oct

  • 27

    Oct

  • 13

    Nov

AMAT

Applied Materials

$45.12

-1.92 (-4.08%)

, AMD

AMD

$29.55

-2.35 (-7.37%)

04:55
08/24/19
08/24
04:55
08/24/19
04:55
Conference/Events
MUFG Securities to hold a tour »

MUFG Securities Tech Tour…

AMAT

Applied Materials

$45.12

-1.92 (-4.08%)

AMD

AMD

$29.55

-2.35 (-7.37%)

ANET

Arista Networks

$223.35

-3.84 (-1.69%)

CHKP

Check Point

$106.84

-2.36 (-2.16%)

CSCO

Cisco

$46.65

-1.55 (-3.22%)

EQIX

Equinix

$549.81

-4.27 (-0.77%)

FLEX

Flex

$9.72

-0.54 (-5.26%)

INTC

Intel

$44.97

-1.79 (-3.83%)

NVDA

Nvidia

$162.51

-8.93 (-5.21%)

OTEX

OpenText

$38.54

-0.57 (-1.46%)

PYPL

PayPal

$106.08

-2.66 (-2.45%)

RNG

RingCentral

$141.50

-0.86 (-0.60%)

SQ

Square

$61.65

-3 (-4.64%)

STX

Seagate

$46.96

-0.62 (-1.30%)

TWLO

Twilio

$127.90

-2.585 (-1.98%)

V

Visa

$175.24

-4.91 (-2.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

  • 28

    Aug

  • 29

    Aug

  • 05

    Sep

  • 06

    Sep

  • 09

    Sep

  • 10

    Sep

  • 16

    Sep

  • 17

    Sep

  • 18

    Sep

  • 19

    Sep

  • 10

    Oct

  • 15

    Oct

  • 24

    Oct

  • 27

    Oct

  • 06

    Nov

  • 13

    Nov

  • 13

    Nov

  • 12

    Dec

  • 16

    Dec

DB

Deutsche Bank

$6.98

-0.19 (-2.65%)

, COF

Capital One

$83.06

-2.68 (-3.13%)

17:57
08/23/19
08/23
17:57
08/23/19
17:57
Periodicals
Deutsche Bank, Capital One won't say if they have Trump's tax returns, NYP says »

Deutsche Bank (DB) and…

DB

Deutsche Bank

$6.98

-0.19 (-2.65%)

COF

Capital One

$83.06

-2.68 (-3.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

MXIM

Maxim Integrated

$52.14

-2.42 (-4.44%)

17:53
08/23/19
08/23
17:53
08/23/19
17:53
Hot Stocks
Maxim Integrated's Jain sells 12,683 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

GLD

SPDR Gold Shares

$144.15

2.77 (1.96%)

17:42
08/23/19
08/23
17:42
08/23/19
17:42
Hot Stocks
SPDR Gold Shares holdings rise to 859.83MT to 854.84MT »

This is the fourth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUMN

Golden Minerals

$0.27

0.0159 (6.38%)

17:33
08/23/19
08/23
17:33
08/23/19
17:33
Hot Stocks
Golden Minerals receives noncompliance notice from NYSE »

Golden Minerals announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMPI

DelMar Pharmaceuticals

$0.77

0.0047 (0.61%)

17:25
08/23/19
08/23
17:25
08/23/19
17:25
Hot Stocks
Intracoastal Capital reports 9.99% passive stake in DelMar Pharmaceuticals »

Intracoastal Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$180.58

-6.44 (-3.44%)

17:22
08/23/19
08/23
17:22
08/23/19
17:22
Hot Stocks
Raytheon awarded $534M Army contract »

Raytheon was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHAL

Amerco

$339.43

-2.97 (-0.87%)

17:21
08/23/19
08/23
17:21
08/23/19
17:21
Hot Stocks
Amerco announces special cash dividend of 50c per share »

The dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTLA

Intellia Therapeutics

$15.77

-1.08 (-6.41%)

17:20
08/23/19
08/23
17:20
08/23/19
17:20
Syndicate
Breaking Syndicate news story on Intellia Therapeutics »

Intellia Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$183.42

-4.19 (-2.23%)

17:19
08/23/19
08/23
17:19
08/23/19
17:19
Hot Stocks
General Dynamics awarded $1.08B Navy contract modification »

General Dynamics has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVLN

Novelion Therapeutics

$0.66

-0.0523 (-7.37%)

17:17
08/23/19
08/23
17:17
08/23/19
17:17
Hot Stocks
Stonepine Capital reports 6.1% passive stake in Novelion Therapeutics »

Stonepine Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$376.85

-8.91 (-2.31%)

17:14
08/23/19
08/23
17:14
08/23/19
17:14
Hot Stocks
Lockheed Martin awarded $2.43B Navy contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCS

OncoSec

$1.84

-0.03 (-1.60%)

17:14
08/23/19
08/23
17:14
08/23/19
17:14
Syndicate
Breaking Syndicate news story on OncoSec »

OncoSec files $50M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNXP

Tonix Pharmaceuticals

$0.42

-0.0249 (-5.60%)

17:09
08/23/19
08/23
17:09
08/23/19
17:09
Syndicate
Breaking Syndicate news story on Tonix Pharmaceuticals »

Tonix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

17:08
08/23/19
08/23
17:08
08/23/19
17:08
General News
Trump to raises tariff rates on Chinese goods, CNBC says »

U.S. President Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATIS

Attis Industries

$1.03

-0.08 (-7.21%)

17:06
08/23/19
08/23
17:06
08/23/19
17:06
Hot Stocks
Attis Industries provides update on status of Nasdaq listing »

Attis Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVEO

Civeo

$1.32

-0.07 (-5.04%)

17:04
08/23/19
08/23
17:04
08/23/19
17:04
Syndicate
Breaking Syndicate news story on Civeo »

Civeo files $300M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGO

Assured Guaranty

$42.56

-1.09 (-2.50%)

16:58
08/23/19
08/23
16:58
08/23/19
16:58
Hot Stocks
Assured Guaranty CEO sells 30,300 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.